Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 8/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.57 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11924817 | 1.00 | KCNA5 (0.57) | KCNA5KCNH2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL10120875 | 0.98 | KCNA5 (0.59) | KCNA5KCNH2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL8907960 | 0.98 | KCNA5 (0.59) | KCNA5KCNH2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL13015207 | 0.84 | CYP2D6 (0.63) | KCNA5KCNH2CYP2D6CYP3A4CYP2C19 | |
| SCHEMBL9366790 | 0.83 | KCNA5 (0.55) | KCNA5KCNH2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL11869847 | 0.82 | KCNA5 (0.48) | KCNA5KCNH2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL1753721 | 0.81 | LMNA (0.44) | KCNA5KCNH2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL31010334 | 0.80 | KCNA5 (0.57) | KCNA5KCNH2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL18782856 | 0.79 | CYP1A2 (0.47) | KCNA5KCNH2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL13649151 | 0.79 | KCNA5 (0.73) | KCNA5KCNH2CYP2D6CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-9000020-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140193363-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100226882-A1 | LINKED DIIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | KCNA5 3425/4885KCNH2 3278/4885CYP2D6 497/4885 |
| US-20100226882-A1 | LINKED DIIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, MAVS | KCNA5 4014/4885KCNH2 2843/4885CYP2D6 365/4885 |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | KCNA5 3425/4885KCNH2 3278/4885CYP2D6 497/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KCNA5 4477/4885KCNH2 3887/4885CYP2D6 594/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | KCNA5 3425/4885KCNH2 3278/4885CYP2D6 497/4885 |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | KCNA5 4126/4885KCNH2 3860/4885CYP2D6 478/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | KCNA5 3286/4885KCNH2 3068/4885CYP2D6 365/4885 |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | KCNA5 4121/4885KCNH2 3093/4885CYP2D6 639/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | KCNA5 4126/4885KCNH2 3860/4885CYP2D6 478/4885 |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | KCNA5 4179/4885KCNH2 3812/4885CYP2D6 309/4885 |
| US-20140193363-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | KCNA5 3425/4885KCNH2 3278/4885CYP2D6 497/4885 |
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | KCNA5 3425/4885KCNH2 3278/4885CYP2D6 497/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | KCNA5 3286/4885KCNH2 3068/4885CYP2D6 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.